RISPERDAL

Source: news.yahoo.com --- 50 days ago
HealthDay - TUESDAY, July 1 (HealthDay News) -- The first generic versions of the antipsychotic drug RISPERDAL (risperidone) were approved Monday by the U.S. Food and Drug Administration. ...

Source: mentalhealth.about.com --- 46 days ago
Information about RISPERDAL (resperidone) - the second atypical antidepressant which has fewer side-effects than older medications. ...

Source: www.globes.co.il --- 50 days ago
RISPERDAL is used as a treatment for schizophrenia and some symptoms of autism. ...

Source: www.medicinenet.com --- 49 days ago
Title: FDA Approves Generic RISPERDAL Category: Health News Created: 7/2/2008 2:00:00 AM Last Editorial Review: 7/2/2008 ...

Source: www.moreover.com --- 49 days ago
IP World Online Jul 3 2008 1:50AM GMT ...

Source: www.medicalnewstoday.com --- 24 days ago
Alkermes, Inc. (NASDAQ: ALKS) today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a supplemental New Drug Application (sNDA) for RISPERDAL® CONSTA® [(risperidone) Long-Acting Injection] to the U.S. Food and Drug Administration (FDA) for approval as monotherapy in the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in adults. ...

Source: www.fiercepharma.com --- 50 days ago
It's a watershed moment: RISPERDAL has gone generic. The Johnson & Johnson antipsychotic med now has copycat competition from Teva Pharmaceutical, which got the final FDA go-ahead yesterday. As soon as the agency gave its OK, Teva started shipping. And no wonder it was ready to go; it has 180 days of market exclusivity, that golden period when a generics maker has no other copycat competition and so the sticker price remains fairly high. Lower than the branded version, of course, but not as low as it will go when other generics makers jump into the market. But wait a minute. J&J quickly struck a blow against that exclusivity. It launched its own authorized generic  to compete with the Teva version. If its drug is going to sell for a lower price, why not capture some of that lower-priced revenue, too? After all, J&J has a lot to lose on a RISPERDAL generic. The branded version sold to the tune of $2.5 billion last year. It's not J&J's biggest drug, but still a major contributor to the drugmaker's income statements with 6 percent of company-wide sales. And RISPERDAL's follow-up, Invega , didn't exactly hit the ground running. It's the end of an era for RISPERDAL. We'll be playing Taps more and more often for blockbuster meds as the sun sets on their patent protection. Some 11 times this year, to be exact. - read the Wall Street Journal Health Blog post Related Articles: RISPERDAL OK'd for children Government widens probes of antipsy ...

Source: www.prescribingreference.com --- 50 days ago
A generic version of Janssen's RISPERDAL (risperidone tablets) has been made available by Teva in 0.25mg, 0.5mg, 1mg, 2mg, 3mg, and 4mg dosage strengths. ...

Source: pharmalicensing.com --- 36 days ago
Other atypicals thrive by capturing specific patient populations, according to a new report from Decision Resources ...

Source: cphtlink.com --- 41 days ago
The Food & Drug Administration has approved the first generic version for the RISPERDAL. Pharmacies can buy varying strengths of risperidone tablets from TEVA Pharmaceuticals or they can purchase an authorized generic version from Patriot Pharmaceuticals, a subsidiary of McNeil-PPC. Both Patriot and Janssen are part of Johnson & Johnson. The Food & Drug Administration cautions [...] ...

Source: www.pharmalot.com --- 50 days ago
Within just a few hours of the announcement that the FDA has approved Teva Pharmaceutical’s generic version of the best-selling antipsychotic, J&J Janssen’s unit has now announced that it will market an authorized generic - in other words, its own generic version of its own brand-name med. The move is hardly surprising, given that RISPERDAL generated [...] ...

Source: www.fwicki.com --- 50 days ago
Johnson & Johnson's blockbuster anti-psychotic drug RISPERDAL will face generic competition, as Teva Pharmaceutical Industries Ltd. on Monday became the first company to receive approval for a generic version. Israel-based Teva received Food and Drug ... ...

Source: www.topix.com --- 50 days ago
NEW YORK -- Johnson & Johnson's blockbuster anti-psychotic drug RISPERDAL will face generic competition, as Teva Pharmaceutical Industries Ltd. ...

Source: neurotalk.psychcentral.com --- 50 days ago
HealthDay - TUESDAY, July 1 (HealthDay News) -- The first generic versions ofthe antipsychotic drug RISPERDAL (risperidone) were approved Monday by... ...

Source: www.topix.com --- 50 days ago
Johnson & Johnson's blockbuster anti-psychotic drug RISPERDAL will face generic competition, as Teva Pharmaceutical Industries Ltd. ...

Source: www.topix.com --- 49 days ago
The FDA has approved the first generic RISPERDAL to treat schizophrenia, bipolar disorder, and other psychiatric conditions. ...

Source: www.fwicki.com --- 24 days ago
Alkermes, Inc. today announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. , submitted a supplemental New Drug Application for RISPERDAL CONSTA [ Long-Acting Injection] to ... ...

Source: www.fwicki.com --- 48 days ago
Main Category: Pharma Industry / Biotech Industry Also Included In: Regulatory Affairs / Drug Approvals Article Date: 03 Jul 2008 Teva Pharmaceutical Industries Ltd. ...

Source: www.fwicki.com --- 50 days ago
NEW YORK : Johnson & Johnson's blockbuster anti-psychotic drug RISPERDAL will face generic competition, as Teva Pharmaceutical Industries Ltd. on Monday became the first company to receive approval for a generic version. Israel-based Teva received U ... ...

Source: www.sensory-processing-disorder.com --- 34 days ago
My Daughter has many tantrums throughout the day and often hits her brother, we are never sure what is going to set her off, though we have ...